Keywords
How to Cite
Abstract
Acute optic vascular neuropathy is a poly etiological condition associated with damage to systemic hemocirculation
in the body. The frequency of vascular diseases of the optic nerve, leading to poor vision and blindness, has increased, more
often in young people. Тhe purpose: to determine the features of the course and treatment of patients with acute vascular
optic neuropathy using the drug Tivargin-N. Material and methods. Examination based on the Department of Inflammatory
Eye Pathology and the Laboratory of Functional Methods of Research of the Organ of Vision of the State University «Institute
of Eye Diseases and Tissue Therapy named after V.P. Filatov NAMNU» and the Department of Ophthalmology of Odesa National
Medical University underwent 85 patients with acute optic vascular neuropathy (ASN), who were divided into 2 groups:
1 group — 43 patients who, in addition to standard treatment, were prescribed Tivargin-N, 2 group — 42 patients who received
only standard therapy. The observation period was 3 months. A standard ophthalmological comprehensive examination of patients
with GSON was carried out. Results. After 3 months of follow-up in the group of patients with Tivargin-N, a significant moderate
relationship was found with the improvement of visual acuity (rs=0.66, p<0.05), total field of vision (rs=0.3, p<0.05), volume
intraocular blood circulation (rs=0.33, p<0.05), as well as an inverse relationship with the number of relapses (rs=-0.22, p<0.05)
and complications (rs =-0.45, p<0.05). Conclusions. The improvement of visual functions after adequate therapy with the use of
L-arginine and pentoxifylline influenced the normalization of metabolism in nerve cells, increasing the reserve capacity of nerve
fiber recovery. There was an increase in visual acuity after 3 months of observation in the group using Tivargin-N by 2 times.
Improvement of visual acuity directly correlated with improvement of hemodynamic indicators, normalization of hemostasis
indicators, restoration of visual field after 3 months of observation.
References
2. Hayreh S, Rojas P, Podhajsky P et al. Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal
vein occlusion. Ophthalmology. 1983;5(90):488-506. doi: 10.1016/s0161-6420(83)34542-5.
3. Hayreh S, Zimmerman M. Fundus changes in central retinal vein occlusion. Retina. 2015;1(35):29-42. DOI: 10.1097/IAE.0000000000000256.
4. Balducci N, Morara M, Veronese S, et al. Optical coherence tomographic angiography in acute arteritic and non-arterial anterior ischemic optic
neuropathy. Graefes Arch Clin Exp Ophthalmol. 2017; 255:2255-2261.
5. Liu Ch, Wu VK, Sun MH, Cao LI, Li YS, Chen HS. Comparison of retinal microvessel density in open-angle glaucoma and non-arteritic anterior
ischemic optic neuropathy. Invest Ophthalmol Vis Sci. 2017; 58:3350-3356.
6. Fard MA, Afzali M, Abdi P, Ebrahimi KB, Mogimi S. Comparison of the defect pattern of the inner plexiform layer of macular ganglion cells in
ischemic optic neuropathy and open-angle glaucoma. Invest Ophthalmol Vis Sci. 2016; 57:1011-1026.
7. Arnold AC. Pathogenesis of nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2003;23:157-163.
8. Hayreh SS. Ischemic optic neuropathies — where are we now? Graefes Arch Clin Exp Ophthalmol. 2013;251:1873-1884.
9. Xie JS, Donaldson L, Margolin E. Papilledema: A review of etiology, pathophysiology, diagnosis, and management. Surv Ophthalmol. 2022 Jul-
Aug;67(4):1135-1159. doi: 10.1016/j.survophthal.2021.11.007. Epub 2021 Nov 20. PMID: 34813854.
10. Chen JJ, Pittock SJ, Flanagan EP, et al. Optic neuritis in the era of biomarkers. Surv Ophthalmol. 2020;65(1):12-17. doi: 10.1016/j.
survophthal.2019.08.001.
11. Biousse V, Newman NJ. Ischemic optic neuropathies. N Engl J Med. 2015;372(25):2428-2436.
12. Zimmermann C, Wimmer M, Haberl RL. L-arginine-mediated vasoreactivity in patients with a risk of stroke. Cerebrovasc. Dis. 2004;17(2-3): 128-133.
13. Arnold AC. Pathogenesis of nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol 2003;23:157-163.
14. Xie JS, Donaldson L, Margolin E. Papilledema: A review of etiology, pathophysiology, diagnosis, and management. Surv Ophthalmol. 2022 Jul-
Aug;67(4):1135-1159. doi: 10.1016/j.survophthal.2021.11.007. Epub 2021 Nov 20. PMID: 34813854.
15. Benussi A, Pilotto A, Premi E et al. Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy,
Italy. Neurology. 2020;95(7): e910-20.